Back to search
FDAFDA · Food and drugs·Recall number D-1543-2014

CYTARAbine for Injection USP, lyophiled in glass vials, 1 gram per vial, Rx only, Distributed by Bedford Laboratories, Bedford, OH 44146, Manufactured by Ben Venue Labs, Inc., Bedford, OH 44146, NDC 55390-808-01

Published August 27, 2014 · Recall initiated: July 31, 2014

Summary

FDA records drug Class II recall D-1543-2014, published August 27, 2014 and initiated July 31, 2014. Recalling firm: Ben Venue Laboratories Inc; Status: Terminated; Reported quantity: 7172 vials; Lot: Lot # 0161-13-2167551; Exp. 07/14 Lot # 0161-13-2176919; Exp. 08/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Crimp defects during visual inspection could affect container closure integrity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ben Venue Laboratories Inc
Distributor
Nationwide
Lot
Lot # 0161-13-2167551; Exp. 07/14 Lot # 0161-13-2176919; Exp. 08/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CYTARAbine for Injection USP, lyophiled in glass vials, 1 gram per vial, Rx only, Distributed by Bedford Laboratories, Bedford, OH 44146, Manufactured by Ben Venue Labs, Inc., Bedford, OH 44146, NDC 55390-808-01 recalled?

Yes. FDA published recall D-1543-2014 on August 27, 2014. Reported hazard: Lack of Assurance of Sterility: Crimp defects during visual inspection could affect container closure integrity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter